Antitumor effect of antisense ODC adenovirus on human prostate cancer cells

Prostate Cancer and Prostatic Diseases

Volumn 8, Issue 3, 2005, Pages 280-286

  Zhang, Y ^a   Liu, Xianxi X ^a   Zhang, B ^a   Hu, H Y ^a   Gong, L ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Antisense technology; Gene therapy; LNCap cell; PC 3 cell; Polyamine biosynthesis

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ADENOVIRUS VECTOR; ORNITHINE DECARBOXYLASE; POLYAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CARCINOGENESIS; CARCINOGENICITY; CELL CYCLE G1 PHASE; CELL GROWTH; CELL INVASION; CELL LEVEL; DRUG EFFECT; GENETIC TRANSDUCTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; WESTERN BLOTTING; XENOGRAFT;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLLAGEN; DRUG COMBINATIONS; FLOW CYTOMETRY; G0 PHASE; G1 PHASE; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; LAMININ; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; OLIGONUCLEOTIDES, ANTISENSE; POLYAMINES; PROSTATIC NEOPLASMS; PROTEOGLYCANS; TETRAZOLIUM SALTS; THIAZOLES; TIME FACTORS;

EID: 31044441641     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500808     Document Type: Article

References (33)

1. Auvinen M, Paasinen A, Andersson LC, Holtta E. Ornithine decarboxylase activity is critical for cell transformation. Nature 1992; 360: 355-358.
2. Moshier JA, Dosescu J, Skunca M, Luk GD. Transformation of NIH/3T3 cells by ornithine decarboxylase overexpression. Cancer Res 1993; 53: 2618-2622.
3. Pegg AE, Xiong H, Feith DJ, Shantz LM. S-adenosylmethionine decarboxylase: Structure, function and regulation by polyamines. Biochem Soc Trans 1998; 26: 580-586.
4. Marton LJ, Pegg AE. Polyamines as targets for therapeutic intervention. Annu Rev Pharmacol Toxicol 1995; 35: 55-91.
5. Moshier JA et al. Isolation and expression of a human ornithine decarboxylase gene. J Biol Chem 1990; 265: 4884-4892.
6. Pegg AE, Madhubala R, Kameji T, Bergeron RJ. Control of ornithine decarboxylase activity in alpha-difluoromethylornithine-resistant L1210 cells by polyamines and synthetic analogues. J Biol Chem 1988; 263: 11008-11014.
7. Sistonen L et al. Activation of the neu tyrosine kinase induces the fos/ jun transcription factor complex, the glucose transporter and ornithine decarboxylase. J Cell Biol 1989; 109: 1911-1919.
8. Auvinen M, Paasinen A, Andersson LC, Holtta E. Ornithine decarboxylase activity is critical for cell transformation. Nature 1992; 360: 355-358.
9. Devens BH et al. Polyamine depletion therapy in prostate cancer. Prostate Cancer Prostatic Dis 2000; 3: 275-279.
10. Glikman P et al. Ornithine decarboxylase activity, prolactin blood levels, and estradiol and progesterone receptors in human breast cancer. Cancer 1987; 60: 2237-2243.
11. Upp Jr JR et al. Polyamine levels and gastrin receptors in colon cancers. Ann Surg 1988; 207: 662-669.
12. Love RR, Astrow SH, Cheeks AM, Havighurst TC. Ornithine decarboxylase (ODC) as a prognostic factor in operable breast cancer. Breast Cancer Res Treat 2003; 79: 329-334.
13. Umemoto S. Antitumor effect of alpha-difluoromethylornithine (DFMO) changes in ornithine decarboxylase (ODC) activity and polyamine (PA) levels in human tumor transplanted into nude mice. Nippon Geka Gakkai Zasshi 1989; 90: 650-660.
14. Zagaja GP et al. Effects of polyamine analogues on prostatic adenocarcinoma cells in vitro and in vivo. Cancer Chemother Pharmacol 1998; 41: 505-512.
15. Guan J, Fan M, Cao S. Reversion of malignant phenotypes of human lung squamous carcinoma cells by ornithine decarboxylase antisense RNA. Zhonghua Zhong Liu Za Zhi 1996; 18: 81-83.
16. Liu X et al. Ornithine decarboxylase activity and its gene expression are increased in benign hyperplastic prostate. Prostate 2000; 43: 83-87.
17. Meager A. Gene Therapy Technologies, Applications and Regulations. John Wiley & Sons: New York, 1999, 81pp.
18. Zhang Y et al. Construction of an antisense RNA recombinant adenovirus vector of the third extron in ODC gene. J Shandong Univ (Health Sci) 2003; 41: 371-374.
19. Prevec L et al. Immune response to HIV-1 gag antigens induced by recombinant adenovirus vectors in mice and rhesus macaque monkeys. J Acquir Immune Defic Syndr 1991; 4: 568-576.
20. Wei D, Tang Z, Chen S. Construction of recombinant adenovirus vector containing mIL-12 using the method of homogenous recombination in bacteria and its expression in vitro with high efficient. Chin J Biochem Mol Biol 2000; 16: 716-721.
21. Fu S, Zen X, Wang X, Liu X. Determination of polyamines in human prostate by high-performance liquid chromatography with fluorescence detection. J Chromatogr B 1998; 709: 297-300.
22. Rockwell SC, Kallman RF, Fajardo LF. Characteristics of a serially transplanted mouse mammary tumor and its tissue-culture-adapted derivative. J Natl Cancer Inst 1972; 49: 735-749.
23. Auvinen M et al. Human ornithine decarboxylase-overproducing NIH3T3 cells induce rapidly growing, highly vascularized tumors in nude mice. Cancer Res 1997; 57: 3016-3025.
24. Metcalf B et al. Catalytic irreversible inhibition of mammalian ornithine decarboxylase by substrate and product analogues. J Am Chem Soc 1978; 100: 2551-2553.
25. Schipper RG et al. Antitumor activity of the polyamine analog N(1), N(11)-diethylnorspermine against human prostate carcinoma cells. Prostate 2000; 44: 313-321.
26. Bello-Fernandez C, Packham G, Cleveland JL. The ornithine decarboxylase gene is a transcriptional target of c-Myc. Proc Natl Acad Sci USA 1993; 90: 7804-7808.
27. Madhubala R, Pegg AE. Inhibition of ornithine decarboxylase and S-adenosylmethionine decarboxylase synthesis by antisense oligodeoxynucleotides. Mol Cell Biochem 1992; 118: 191-195.
28. Mi Z et al. Human prostatic carcinoma cell lines display altered regulation of polyamine transport in response to polyamine analogs and inhibitors. Prostate 1998; 34: 51-60.
29. Ko SC et al. Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model. Hum Gene Ther 1996; 7: 1683-1691.
30. Thomas T, Kiang DT. Additive growth-inhibitory effects of DL-alpha-difluoromethylornithine and antiestrogens on MCF-7 breast cancer cell line. Biochem Biophys Res Commun 1987; 148: 1338-1345.
31. Alm K et al. Treatment of cells with the polyamine analog N, N11-diethylnorspermine retards S phase progression within one cell cycle. Eur J Biochem 2000; 267: 4157-4164.
32. da Rocha AB et al. Protein kinase C-mediated in vitro invasion of human glioma cells through extracellular-signal-regulated kinase and ornithine decarboxylase. Pathobiology 2000; 68: 113-123.
33. Manni A et al. Influence of polyamines on in vitro and in vivo features of aggressive and metastatic behavior by human breast cancer cells. Clin Exp Metastasis 2002; 19: 95-105.